CLINICAL_TRIALS
trial_result
· 2014-05-02
Clinical Trial Update: An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia [Phase 3]
Summary
Phase 3 open-label study of conivaptan (YM087) in patients with euvolemic or hypervolemic hyponatremia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cumberland Pharmaceuticals | Conditions: Hyponatremia | Phase 3 | Status: COMPLETED